

07.02.2018

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

**SUB:UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED
DECEMBER 31,2017**

The Board of Directors of the Company at their meeting held today have approved the Un-audited financial Results for the quarter and nine months ended December 31,2017.Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose:

1. Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31,2017
2. Limited Review Report as placed before the Board for the above Un-audited Financial Results for the quarter and nine months ended December 31, 2017.

The meeting of the Board of Directors commenced at 11.30 A.M and concluded at 1.25 P.M

Kindly take the same on your records.

Thanking You,

Yours Faithfully,

For Caplin Point Laboratories Limited


Company Secretary
Enclosure: As above.

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID:info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND NINE MONTHS ENDED 31st DECEMBER 2017

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Part I	Particulars	Three Months Ended			Nine Months Ended		Financial Year Ended
		31.12.2017 (1)	30.09.2017 (2)	31.12.2016 (3)	31.12.2017 (4)	31.12.2016 (5)	31.03.2017 (6)
		(Unaudited)					(Audited)
		INR In Lakhs					
	Income:						
I	Revenue from operations	11,083.42	10,340.64	8,767.44	31,613.26	24,619.63	34,436.08
II	Dividend from subsidiary	-	1,139.50	-	1,139.50	-	-
III	Other income	224.56	274.23	311.67	885.00	973.94	970.10
IV	Total Income (I+II+III)	11,307.98	11,754.37	9,079.11	33,637.76	25,593.57	35,406.18
	Expenses:						
	a. Cost of materials consumed	2511.68	2405.24	1,318.97	6,942.16	4,758.37	6,447.19
	b. Purchase of traded goods	2174.19	2008.28	2,630.97	6,586.09	7,435.37	9,734.11
	c. Changes in inventories of finished goods, stock in trade and work in progress	166.74	(99.38)	(134.75)	28.03	(127.76)	12.40
	d. Employee benefit expenses	986.76	1016.15	876.01	2,900.33	2,215.41	3,061.64
	e. Finance cost	1.46	1.69	1.84	4.76	9.28	12.75
	f. Depreciation & Amortisation Expenses	452.47	444.45	297.25	1,281.37	822.93	1,325.99
	g. Exchange Fluctuation Loss	-	-	-	-	2.95	-
	h. Other Expenses	1546.48	1409.38	1,779.06	4,460.90	4,178.81	5,554.27
	i. Total Expenses	7,839.78	7,185.81	6,769.35	22,203.64	19,295.36	26,148.35
VI	Profit before exceptional items and Tax (IV-V)	3,468.20	4,568.56	2,309.76	11,434.12	6,298.21	9,257.83
VII	Exceptional items	-	-	-	-	-	-
VIII	Profit Before Tax (VI-VII)	3,468.20	4,568.56	2,309.76	11,434.12	6,298.21	9,257.83
IX	Tax Expenses						
	(1) Current Tax	924.53	1232.32	450.46	3,040.48	1,328.98	1,937.42
	(2) MAT Credit	-	-	-	-	-	(434.95)
	(3) Deferred Tax	185.12	61.25	104.79	320.36	78.68	723.65
	Total Tax Expenses	1,109.65	1,293.57	555.25	3,360.84	1,407.66	2,226.12
X	Net Profit for the period (VIII-IX)	2,358.55	3,274.99	1,754.51	8,073.28	4,890.55	7,031.71
XI	Other Comprehensive Income - Net of Income Tax	4.05	4.19	4.05	12.37	12.08	16.16
XII	Total Comprehensive Income For The Period (X+XI)	2,362.60	3,279.18	1,758.56	8,085.65	4,902.63	7,047.87
XIII	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs 2/- each wef 20 Oct 2016)	1,511.53	1,511.53	1,511.00	1,511.53	1,511.00	1,511.53
XIV	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						18,479.76
XV	Earnings/(Loss) Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share (post sub division of shares)						
	(a) Basic (in Rupees)	3.13	4.34	2.33	10.70	6.48	9.30
	(b) Diluted (in Rupees)	3.11	4.32	2.33	10.65	6.48	9.30



Signature

Notes :

1) The Company adopted Indian Accounting Standards ("Ind AS") from 1st April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting pronouncement generally accepted in India. Financial results of all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2) Reconciliation between financial results as previously reported under Previous GAAP and Ind AS presented are as under:

a. Profit Reconciliation

Particulars	INR in lakhs		
	Three months ended 31.12.2016	Nine months ended 31.12.2016	Year ended 31.03. 2017
Net profit under previous I GAAP	1,769.90	4,896.44	7,086.32
Income on account of fair Value Adjustment of Rental Deposit	0.38	1.17	1.56
Amortisation of Rental Deposit	(0.42)	(1.23)	(1.64)
Fair Value measurement of Mutual fund	-	-	10.49
Actuarial (gain) / Loss on employee defined benefit funds recognized in Other Comprehensive Income	(4.05)	(12.08)	(16.16)
Impact on rent straight lining	0.67	2.01	2.68
Other fair value measurement impact	(20.10)	(20.12)	(80.43)
Deferred Tax	8.13	24.36	28.89
Net Profit as per Ind AS	1,754.51	4,890.55	7,031.71
Other Comprehensive Income - Net of Income Tax	4.05	12.08	16.16
Total Comprehensive Income For The Period	1,758.56	4,902.63	7,047.87

- 3) The unaudited results have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 7th February 2018.
- 4) The Ind AS compliant corresponding figures for the year ended 31st March 2017, the corresponding period of three months and nine months ended 31st December 2016 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs. The unaudited results for three months period ended 31st December 2017 have been subjected to a limited review by statutory auditors of the Company.
- 5) The total income of immediate previous three months period ended 30th September 2017 includes a dividend income of Rs 1139.50 lakhs from 100% foreign subsidiary in Hong Kong, as compared to NIL during the three months period under review. The total income for the nine month period ended 31st December 2017 includes the said dividend of Rs 1139.50 lakhs and the provision for current tax includes the tax liability under the provisions of Income Tax Act, 1961 on such dividend income.
- 6) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 7) With effect from 20th October, 2016 the equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each and accordingly, 7,55,50,000 number of equity shares were outstanding subsequent to such sub-division.
- 8) During the three months period ended 31st March 2017, the Company had allotted 26,750 equity shares of Rs 2/- each under the Employee Stock Option Scheme 2015 and the total number of equity shares of the Company stands at 7,55,76,750 as on 31st March 2017 and therefrom.
- 9) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai
Date 7th February 2018




Dr Sridhar Ganesan
Managing Director

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbasai", # 3, Lakshmanan Street, T. Nagar, Chennai 600 017

CIN - L24251TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28151952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND NINE MONTHS ENDED 31st DECEMBER 2017

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Part I	Three Months ended		Nine Months Ended		Financial Year Ended	
	31.12. 2017 (1)	30.09.2017 (2)	31.12. 2016 (3)	31.12. 2017 (4)		31.12. 2016 (5)
Particulars						
	(Unaudited)					(Audited)
	INR in lakhs					
I	14,160.80	13,131.13	10,279.04	39,643.12	28,359.14	40,164.85
II	232.76	357.69	220.11	976.66	559.50	995.53
III	14,393.56	13,488.82	10,499.15	40,619.78	28,918.63	41,160.38
IV						
a. Cost of materials consumed	2,511.68	2,405.23	1,338.97	6,942.15	4,788.37	6,477.70
b. Purchase of traded goods	3,859.29	3,404.91	2,985.06	10,629.09	8,766.14	11,941.57
c. Changes in inventories of finished goods, stock in trade and work in progress	166.74	(99.38)	(136.88)	28.03	(127.76)	73.62
d. Employee benefit expenses	986.76	1,016.15	876.48	2,900.33	2,225.08	3,084.59
e. Finance cost	1.46	1.69	1.84	4.76	9.28	12.75
f. Depreciation & Amortisation Expenses	452.47	445.01	298.05	1,281.93	830.74	1,329.84
g. Exchange Fluctuation Loss	-	-	-	-	2.95	-
h. Other Expenses	1,557.48	1,467.95	2,078.87	4,538.47	4,537.01	6,145.61
i. Total Expenses	9,535.88	8,641.57	7,442.39	26,324.77	21,031.81	29,065.68
V	4,857.68	4,847.25	3,056.76	14,295.01	7,886.83	12,094.70
VI	-	-	-	-	-	-
VII	4,857.68	4,847.25	3,056.76	14,295.01	7,886.83	12,094.70
VIII						
(1) Current Tax	924.53	1,232.32	575.46	3,040.48	1,538.98	2,255.70
(2) MAT credit	-	-	-	-	-	(434.95)
(3) Deferred Tax	185.12	61.25	104.79	320.36	78.68	723.66
Total Tax Expenses	1,109.65	1,293.57	680.25	3,360.84	1,617.66	2,544.41
IX	3,748.03	3,553.68	2,376.51	10,934.17	6,269.17	9,550.29
X	4.05	4.19	4.05	12.37	12.08	16.16
XI	3,752.08	3,557.87	2,380.56	10,946.54	6,281.25	9,566.45
XII						
Owners of the Company	3,752.49	3,557.17	2,376.31	10,942.99	6,262.89	9,561.24
Non- controlling interests	(4.46)	(3.49)	0.20	(8.82)	6.28	(10.95)
XIII	3,748.03	3,553.68	2,376.51	10,934.17	6,269.17	9,550.29
Owners of the Company	3,756.54	3,561.36	2,380.36	10,955.36	6,274.97	9,577.40
Non- controlling interests	(4.46)	(3.49)	0.20	(8.82)	6.28	(10.95)
XIV	1,511.53	1,511.53	1,511.00	1,511.53	1,511.00	1,511.53
XV						20,944.46
XVI						
(a) Basic (in Rupees)	4.96	4.71	3.15	14.48	8.31	12.65
(b) Diluted (in Rupees)	4.94	4.69	3.15	14.41	8.31	12.65



Signature

Notes:

- 1) The Company adopted Indian Accounting Standards ("Ind AS") from 1st April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting pronouncement generally accepted in India. Financial results of all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- 2) Reconciliation between financial results as previously reported under Previous GAAP and Ind AS presented are as under:
- a. Profit Reconciliation

Particulars	INR in Lakhs		
	Three months ended 31.12.2016	Nine months ended 31.12.2016	Year ended 31.03.2017
Net profit under previous I GAAP	2,391.90	6,275.06	9,604.90
Income on account of fair Value Adjustment of Rental Depos	0.38	1.17	1.56
Amortisation of Rental Deposit	(0.42)	(1.23)	(1.64)
Fair Value measurement of Mutual fund	-	-	10.49
Actuarial (gain) / Loss on employee defined benefit funds recognized in Other Comprehensive Income	(4.05)	(12.08)	(16.16)
Impact on rent straight lining	0.67	2.01	2.68
Other fair value measurement impact	(20.10)	(20.12)	(80.43)
Deferred Tax	8.13	24.36	28.89
Net Profit as per Ind AS	2,376.51	6,269.17	9,550.29
Other Comprehensive Income - Net of Income Tax	4.05	12.08	16.16
Total Comprehensive Income For The Period	2,380.56	6,281.25	9,566.45
Less: Non Controlling Interest	0.20	6.28	(10.95)
Total Comprehensive Income attributable to owners	2,380.36	6,274.97	9,577.40

- 3) The unaudited results have been reviewed by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 7th February 2018.
- 4) The Ind AS compliant corresponding figures for the year ended 31st March 2017, the corresponding previous three months and nine months period ended 31st December 2016 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs. The unaudited results for the three months period ended 31st December 2017 have been subjected to a limited review by statutory auditors of the Company.
- 5) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 6) Provision for current tax for the nine months period ended 31st December 2017 includes the tax liability under the provisions of Income Tax Act, 1961 on the dividend distributed by 100% foreign subsidiary in Hong Kong.
- 7) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr Sridhar Ganesan
Managing Director

Place : Chennai
Date : 7th February 2018





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Standalone Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of **Caplin Point Laboratories Limited** for the quarter ended 31st December 2017, being submitted by the company pursuant of the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 31st December 2016 including the reconciliation of the profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these financials results have been approved by the company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 7th February 2018. Our responsibility is to issue report on these financials statements based on our review

Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered accounts of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : 07/02/2018



for M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No:
004915S/S200036


K.PARTHASARATHY
Partner
Membership No:018394



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Consolidated Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Caplin Point Laboratories Limited** ("the company"), its subsidiaries (the company, its subsidiaries constitute "the group") for the quarter ended 31st December 2017, being submitted by the company pursuant to the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 31st December 2016 including the reconciliation of the profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these financials results have been approved by the company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 7th February 2018. Our responsibility is to issue report on these financials statements based on our review.

Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered accounts of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statements includes the results of the following entities:

1. Argus Salud Pharma LLP
2. Caplin Point Far East Limited
3. Caplin Point Laboratories Colombia SAS



Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies act, 2013 read with relevant rules there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No:004915S/S200036



K.PARTHASARATHY
Partner

Membership No:018394

Place : Chennai
Date : 07/02/2018

